A follow-up study of a population of schizophrenic patients treated with clozapine

• Published in: Progress in neuro-psychopharmacology & biological psychiatry 2001-11, Vol.25 (8), p.1481-1495
• Main Authors: Bourin, Michel, Guitton, Bernard, Dailly, Eric, Hery, Pascale, Jolliet, Pascale
• Format: Article
• Language: English
• Subjects: Adult; agranulocytosis; Agranulocytosis - chemically induced; Agranulocytosis - epidemiology; Antipsychotic Agents - adverse effects; Antipsychotic Agents - pharmacology; Antipsychotic Agents - therapeutic use; Biological and medical sciences; clozapine; Clozapine - adverse effects; Clozapine - pharmacology; Clozapine - therapeutic use; Drug Resistance; Drug toxicity and drugs side effects treatment; Female; Follow-Up Studies; Humans; Incidence; Leukocyte Count; Male; Medical sciences; neutropenia; Neutropenia - chemically induced; Neutropenia - epidemiology; Pharmacology. Drug treatments; Retrospective Studies; Risk Factors; schizophrenia; Schizophrenia - drug therapy; Sex Factors; Toxicity: blood; Treatment Outcome
• ISSN: 0278-5846; 1878-4216
• DOI: 10.1016/S0278-5846(01)00213-5

1. Clozapine is a dibenzodiazepine neuroleptic which presents the advantage of not having undesirable neurological side-effects. Its efficacy for the treatment of the symptoms of schizophrenia is known, but the use of clozapine is limited to treatment-resistant schizophrenic patients as it induces agranulocytosis with a higher incidence than that of other neuroleptic drugs. 2. The present study was designed in order to evaluate the benefit/risk of chronic treatment. The analysis was performed using the files of schizophrenic patients. These patients were not stabilized by a classical neuroleptic treatment and/or presented individual secondary effects. 3. Clozapine induced neutropenia and 1 case of agranulocytosis in 3 females. Analysis of leukocyte expression highlighted some premonitory symptoms in patients who presented neutropenia. The observation of 2 to 3 early successive peaks in leukocyte expression (between the third and tenth week of treatment) could be predictive of neutropenia in the 3 to 4 months of treatment. 4. The patients who presented a lower leukocyte base-line following a peak had a higher risk, of developing neutropenia. This might explain some late accidents beyond the first six months of treatment. 5. The present study confirmed the advantages of clozapine treatment and demonstrated that the risk of neutropenia may be diminished by the detection of premonitory symptoms and the early monitoring of patients at risk i.e. female patients and subjects with a lower leukocyte base-line.